BridgeBio Oncology Therapeutics (BBOT) released a peer‑reviewed study in Cancer Discovery that presents preclinical data for its lead pan‑KRAS inhibitor, BBO‑11818. The paper, titled “Discovery of BBO‑11818, a Potent and Selective Non‑covalent Inhibitor of (ON) and (OFF) KRAS with Activity Against Multiple Oncogenic Mutants,” demonstrates robust tumor growth inhibition across KRAS G12D and G12V models and shows greater than 500‑fold selectivity over HRAS and NRAS.
The preclinical results underscore BBO‑11818’s unique ability to target both the active (ON) and inactive (OFF) states of KRAS, a feature that distinguishes it from existing G12C‑specific inhibitors. In vitro assays revealed potent activity against a panel of KRAS mutants, and in vivo xenograft studies confirmed significant tumor regression in models driven by G12D and G12V mutations, which are responsible for a large share of KRAS‑driven cancers.
In addition to the preclinical data, BBOT disclosed preliminary Phase 1 results from the KONQUER‑101 trial. The study reported a confirmed partial response in a patient with pancreatic ductal adenocarcinoma, achieving a 56 % reduction in tumor burden, and no dose‑limiting toxicities were observed. These early clinical signals suggest that BBO‑11818 may offer therapeutic benefit beyond the limited approvals for KRAS G12C inhibitors.
BBOT’s earnings for the quarter ended February 28 2026 beat analyst expectations, reporting an earnings per share of ($0.49) versus a consensus estimate of ($0.67). The beat was driven by disciplined cost management and the absence of large one‑time charges, allowing the company to maintain profitability despite ongoing investment in clinical development. BBOT’s cash position remains strong, with a current ratio of 13.33, providing financial flexibility to fund the next phases of its pipeline and potential combination studies with its PI3Kα breaker, BBO‑10203.
The announcement was met with a positive market reaction, with analysts noting the significance of the peer‑reviewed data and the early clinical signals. BBOT has indicated that additional data from KONQUER‑101 will be available in the second half of 2026 and that combination studies with BBO‑10203 will commence later in 2026, positioning the company to pursue a broader therapeutic strategy in KRAS‑driven malignancies.
The peer‑reviewed publication and early clinical results reinforce BBOT’s competitive positioning in the KRAS inhibitor space, where unmet need remains high for mutations beyond G12C. The company’s strong cash reserves and disciplined cost structure support continued investment in its pipeline, while the upcoming data releases and combination studies are expected to further validate BBO‑11818’s clinical potential and inform future financing plans.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.